COMING SOON
2.1 mRNA Vaccines Overview
2.2 mRNA Vaccines v/s Other Cancer Therapeutic Approaches
2.3 mRNA Vaccines v/s Other Vaccines
3.1 Current Market Trends
3.2 Future Market Opportunities
4.1 By Phase
4.2 By Company
4.3 By Country
4.4 By Indication
5.1 Research
5.2 Preclinical
5.3 Phase I
5.4 Phase I/II
5.5 Phase II
5.6 Phase II/III
5.7 Phase III
6.1 Breast Cancer
6.2 Brain Cancers
6.3 Melanoma
6.4 Head and Neck Cancers
6.5 Cervical Cancer
6.6 Lung Cancer
6.7 Gastrointestinal Cancers
7.1 US
7.2 Russia
7.3 China
7.4 Australia
7.5 Europe
7.6 Canada
7.7 UK
9.1 BioNTech
9.2 Combined Therapeutics
9.3 CureVac
9.4 EpiVax
9.5 HDT Bio
9.6 Immorna
9.7 Immune Design
9.8 MDimune
9.9 Moderna Therapeutics
9.10 NeoCura
9.11 pHion Therapeutics
9.12 Providence Therapeutics
9.13 RinuaGene
9.14 RNAimmune
9.15 TransCode Therapeutics
Figure 3-1: Global mRNA Cancer Vaccines Market - Future Market Opportunities
Figure 4-1: Global – Number Of mRNA Cancer Vaccines In Clinical Trials By Phase, 2026
Figure 4-2: Global – Number Of mRNA Cancer Vaccines In Clinical Trials By Company, 2026
Figure 4-3: Global – Number Of mRNA Cancer Vaccines In Clinical Trials By Country, 2026
Figure 4-4: Global – Number Of mRNA Cancer Vaccines In Clinical Trials By Indication, 2026
Figure 6-1: KEYNOTE-942 Phase II (NCT03897881) Study – Initiation and Completion Year
Figure 6-2: INTerpath-001 Phase III (NCT05933577) Study – Initiation and Completion Year
Figure 6-3: AHEAD-MERIT Phase II (NCT04534205) Study – Initiation and Completion Year
Figure 6-4: KEYNOTE-603 Phase I (NCT03313778) Study – Initiation and Completion Year
Figure 6-5: EVM14C101 Phase I/II (NCT07095868) Study – Initiation and Completion Year
Figure 6-6: RG002-A1201 Phase I/II (NCT06273553) Study – Initiation and Completion Year
Figure 6-7: INTerpath-002 Phase III (NCT06077760) Study – Initiation and Completion Year
Figure 6-8: LuCa-MERIT-1 Phase I (NCT05142189) Study – Initiation and Completion Year
Figure 6-9: EMPOWERVAX Lung 1 Phase II (NCT05142189) Study – Initiation and Completion Year
Figure 6-10: 19-039 Phase I (NCT04161755) Study – Initiation and Completion Year
Figure 6-11: IMCODE003 Phase II (NCT05968326) Study – Initiation and Completion Year
Figure 6-12: BNT122-01 Phase II (NCT04486378) Study – Initiation and Completion Year
Figure 8-1: BioNTech – uRNA Products
Figure 8-2: BioNTech – iNeST Technology
Figure 8-3: CureVac – Proprietary Method For Generation Of mRNA Therapeutics
Figure 8-4: Moderna - mRNA Technology
Figure 8-5: NeoCura – NeoCura Ag Platform
Figure 8-6: Providence Therapeutic - mRNA Medicines Platform Benefits
Figure 8-7: RinuaGene - Targeted Delivery
Figure 8-8: RinuaGene - RNA Engineering
Figure 8-9: RinuaGene - Robust CMC
Figure 8-10: RinuaGene - Data Science and AI
Figure 8-11: MOPCTx Platform - Molecular Adjuvantation Cancer Vaccine Workflow
List Of Tables
Table 2-1: mRNA Vaccines v/s Other Cancer Therapeutic Approaches
Table 2-2: mRNA-Based Cancer Vaccines v/s Other Cancer Vaccines
Table 3-1: Regulatory Designations Granted To Investigational mRNA Cancer Vaccines a
